Relatro^™ 25

Indication:
In Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g. spinal cord injury, stroke, cerebral palsy, multiple sclerosis etc.). Dantrolene is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.

Dosage & Administration:
For Use in treatment of Chronic Spasticity:
Adults:
Initial dose: 25 mg once daily for seven days. Maintenance dose: 25-50 mg thrice daily for seven days. Maximum daily dose: 100 mg orally 4 times daily.
Pediatric Patients:
Initial dose: 0.5 mg/kg once daily for seven days. Maintenance dose: 0.5-1 mg/kg thrice daily for seven days.

Preparation:
Relatro^™ 25 Capsule: Each box contains 20 capsules in alu-alu blister pack.